Literature DB >> 24936998

Prevalence of clinical (major) depression in general practice using the DSM-IV version of PRIME-MD.

O Christensen Sven Bundgaard Per Bech.   

Abstract

INTRODUCTION: PRIME-MD (Primary Care Evaluation of Mental Disorder) has been developed to detect the most frequent mental disorders in general practice.
METHOD: A prevalence study with the Danish PRIME-MD's module for major depression was carried out by general practitioners. In total, 16 practices and 2501 patients were involved in the study.
RESULTS: The patient questionnaire part of the PRIME-MD was completed by more than 95% of the patients, indicating a high applicability. Around 8% of all patients included suffered from major depression. Of these, the ratio of females to males was 2:1. Three factors were identified in the questionnaire: depression, psychosomatic distress, and alcohol use. Compared to the non-depressed patients, the patients with major depression evaluated their health condition as being considerably impaired.
CONCLUSION: PRIME-MD is highly applicable in general practice. ( Int J Psych Clin Pract 2001; 5:49-54).

Entities:  

Keywords:  Major Depression Diagnostic Instruments General Practice

Year:  2001        PMID: 24936998     DOI: 10.1080/136515001300225196

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  2 in total

1.  The Clinical Effectiveness of Blended Cognitive Behavioral Therapy Compared With Face-to-Face Cognitive Behavioral Therapy for Adult Depression: Randomized Controlled Noninferiority Trial.

Authors:  Kim Mathiasen; Tonny E Andersen; Mia Beck Lichtenstein; Lars Holger Ehlers; Heleen Riper; Annet Kleiboer; Kirsten K Roessler
Journal:  J Med Internet Res       Date:  2022-09-07       Impact factor: 7.076

2.  Guided Internet-Based Cognitive Behavioral Therapy for Adult Depression and Anxiety in Routine Secondary Care: Observational Study.

Authors:  Kim Mathiasen; Heleen Riper; Tonny E Andersen; Kirsten K Roessler
Journal:  J Med Internet Res       Date:  2018-11-28       Impact factor: 5.428

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.